Walleye Trading
VIRX

Walleye Trading’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Walleye Trading’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-24
Closed -$3K – 5528
2016
Q2 		$3K Buy
24
+1
+4% +$111 ﹤0.01% 5083
2016
Q1 		$3K Buy
23
+21
+1,050% +$3.18K ﹤0.01% 5069
2015
Q4 		$0 Sell
2
-4
-67% -$748 ﹤0.01% 5772
2015
Q3 		$1K Buy
+6
New +$2.17K ﹤0.01% 4849

Other funds holding VIRX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Walleye Trading's VIRX Position: Q3 2016 in Review

Walleye Trading sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2016, closing a stake of 24 shares — an estimated $3K sold.

Walleye Trading first reported a position in VIRX in Q3 2015 and held it in 4 quarters. The position peaked at $3K in Q2 2016. 40 funds tracked by Wall St. Rank hold VIRX as of Q3 2016.

  • Walleye Trading reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
  • Walleye Trading sold 24 Viracta Therapeutics, Inc. Common Stock shares in Q3 2016, an estimated $3K.
  • Walleye Trading first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2015 and held it in 4 quarters.
  • Walleye Trading's Viracta Therapeutics, Inc. Common Stock position peaked at $3K in Q2 2016.
  • 40 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2016.

Based on Walleye Trading's 13F filing for Q3 2016, filed 14 Nov 2016.